His new research shows that people injecting two doses are at risk of positive for NCOV three times lower than those who have not been vaccinated.

The study of the Covid-19 React-1 monitoring program, led by the Royal University of London and Ipsos Mori Company, based on analyzing the test results of more than 98,000 people from June 24 to July 12.

Vaccine Astrazeneca and the injections are prepared at a vaccination point in Luton, UK in March. Photo: AP.

The study added that if the vaccinated people adequently infected with NCOV, they also risked the virus transmission to other people lower, due to small viral loads.

These findings show that two doses of vaccines provide good protective classes before the risk of infection, Professor Paul Elliott, Public Health School of Royal London University, said.

For over 98,000 samples, scientists recorded 527 positive samples, equivalent to the rate of 0.63%.

Results of sequencing the gene of 254 in 527 samples for Delta transformation results.